Frontlight ResearchEarly access
Chronic kidney disease trials in Japan
11 of 14 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Not yet taking people in JapanA Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both
- Where
- Aichi, Arakawa-ku, Tokyo, Chiba-shi, Chiba, Chikushino-shi, Fukuoka, Gifu, Ibaraki, Kamakura-shi, Kanagawa, Koriyama-shi, Fukushima, Minato-ku, Tokyo, Mito-shi, Ibaraki, Oita-shi, Oita,, Sendai, Miyagi, Tamana-shi, Kumamoto, Tokyo, Tsu-shi, Mie, Wakayama
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07931547 · EU 2026-525471-13-00 - Phase 3Taking peopleA Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
- Where
- Aira, Amagasaki-shi, Beppu-shi, Chigasaki-shi, Fujinomiya-shi, Hakodate-shi, Hamamatsu, Higashihiroshima-shi, Iizuka-shi, Inashiki-gun, Iwata-shi, Kagoshima, Kamakura-shi, Kanazawa, Kashiwara-shi, Kasugai-shi, Kita-ku, Kitakyushu, Kitakyushu-shi, Kobe, Kumagaya-shi, Kurashiki-shi, Kuse-gun, Kuwana-shi, Kyoto, Matsusaka-shi, Matsuyama, Meguro-ku, Minatoku, Minokamo Shi, Miyakonojo-shi, Morioka, Nagaoka-shi, Naka, Narita-shi, Obihiro-shi, Ōita, Ōme, Ōmihachiman, Osaka, Saga, Sapporo, Sendai, Shibuya-ku, tabashi City, Tanabe-shi, Toyoake-shi, Toyohashi, Tsu, Yaizu-shi, Yokohama, Yoshida-gun
- Age
- 18 years and over
- People
- 5,000 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06742723 · EU 2023-506460-14-00 - Phase 3Taking peopleA Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
- Where
- Chūōku, Hamadayama, Suginami-ku, Izumisano, Kobe, Kofu, Kumamoto, Shinjuku-ku, Takarazuka, Uji, Wakayama
- Age
- 50 years and over
- People
- 7,140 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07241390 · EU 2025-523123-22-00 - Phase 2Taking peopleDose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP
- Where
- Kamakura, Kasugai, Matsubara, Matsudo
- Age
- 18 years to 80 years
- People
- 180 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07830719 · EU 2026-525974-21-00 - Phase 3Active, not recruitingA Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- Where
- Chiba, Kasugai, Kawasaki, Kyoto, Matsumoto, Niigata, Okayama, Ōmihachiman, Osaka, Sapporo, Sendai, Toyoake, Toyota, Yokohama
- Age
- 18 years to 100 years
- People
- 540 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04557462 · EU 2023-508690-92-00 - Phase 3Taking peopleA Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
- Where
- Ageo, Asahi-shi, Chiba, Fukaya, Fukui-shi, Izumisano, Izunokuni-shi, Kariya, Kisarazu-shi, Kita-ku, Kitakyusyu-shi, Kofu, Koga-shi, Komatsu-shi, Koshigaya-shi, Kumagaya-shi, Kumamoto, Kurashiki-shi, Kuwana-shi, Kyoto, Matsumoto-shi, Minamiuonuma, Minatoku, Minokamo Shi, Morioka, Nagoya, Naka, Nerima-ku, Osaka, Sendai, Takatsuki-shi, Toride-shi, Tsu, Urayasu, Yokohama
- Age
- 18 years to 99 years
- People
- 2,800 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07624305 · EU 2026-526114-90-00 - Phase 2/3Taking peopleCombined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- Where
- Hashima-gun, Higashiosaka-shi, Hiroshima, Hokkaido, Ibaraki, Ichinomiya-shi, Inashiki-gun, Kagoshima, Kamakura-shi, Kanazawa, Kitakyushu-shi, Kurume, Kurume-shi, Kusatsu-shi, Kyoto, Maebashi, Matsubara-shi, Nagaoka-Shi, Nagoya, Ogaki-Shi, Ōmihachiman, Oyama-shi, Sakaimachi, Sapporo, Shinjuku-Ku, Takasaki-Shi, Tsukuba, Ube-shi, Urayasu-shi, Yamagata, Yokohama, Yonago-shi
- Age
- 18 years and over
- People
- 3,110 worldwide
- Run by
- CSL Behring
See details and how to joinNCT05485961 · EU 2022-500273-14-00 - Phase 3Taking peopleA Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
- Where
- Aira, Akita, Asahikawa-shi, Chūōku, Fujisawa-shi, Fukuoka, Hachioji-shi, Hamamatsu, Hiroshima, Ichikawa-shi, Ina-shi, Iruma-Gun, Izunokuni-shi, Kamakura-shi, Kamiina-gun, Kanazawa, Kasugai-shi, Kasuga-shi, Kawachinagano-shi, Kitakyushu, Kitakyushu-shi, Kumamoto, Kurume, Kuwana-shi, Matsumoto-shi, Minatoku, Minokamo Shi, Moriyama-shi, Nagoya, Naka, Ōita, Okayama, Osaka, Oyama-shi, Sakaishi, Sakushu, Sapporo, Sasebo-shi, Shinjuku-ku, Suita-shi, Suwa-shi, Takasago-shi, Tsu, Ueda-shi, Ushiku-shi, Utsunomiya, Yokohama
- Age
- 18 years and over
- People
- 7,000 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07753993 · EU 2025-523994-41-00 - Phase 3Taking peopleA Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
- Where
- Chigasaki-shi, Chikushino-shi, Gifu, Kagoshima, Kitakyushu, Kumamoto, Kyoto, Maebashi, Nagoya, Osaka, Sapporo, Suita-shi, Tachikawa-shi, Toyota-Shi
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07662135 · EU 2025-523940-12-00 - Phase 1Taking peopleA Study of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus
- Where
- Fukuoka
- Age
- 18 years to 64 years
- People
- 120
- Run by
- Ono Pharmaceutical Co., Ltd.
See details and how to joinNCT07619157 - Phase 2Taking peopleA Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
- Where
- Aichi, Ibaraki, Kanagawa, Kita-ku, Tokyo, Koriyama-shi, Fukushima, Saitama, Sendai-shi, Miyagi, Siga, Tokyo
- Age
- 18 years and over
- People
- 465 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06717698 · EU 2024-510846-15-00